Connected Injectable Drug Delivery Devices Market By Type 2022 | IndustryARC
  • 1-614-588-8538 (Ext: 101)
  • US Toll Free

Connected Injectable Drug Delivery Devices Market
Connected Injectable Drug Delivery Devices Market: By Type (Conventional, Self-Injection, Others); By Connected Technology (Wireless, Bluetooth, Apps, NFC); By Disease (Anaphylaxis, Cardiovascular, Diabetes, etc); By Geography - (2015-2022)
Report Code : HCR 1211
Updated Date: 27 September, 2017  
17

Copies sold

    Client Rating

  • Report Description
  • Table of Contents
  • Customization Options
Connected injectable drug delivery devices reminds and records patients dosing pattern and makes it accessible to healthcare professionals for significant understanding about the patient condition. These drug delivery devices helps in addressing the patient consistence issues with the medication treatment, disease management protocols which are major concerns for healthcare professionals and pharmaceutical industry. Before bringing a connected health offering to life, it is important to understand the fundamentals of patient-centric design. One of the most successful elements in fulfilling the need for patient-centric design is human factors analysis, which benefits the patient by making injection systems more comfortable and user-friendly.

Connected injectable drug delivery devices market is comprehended by device type, technology, application and end user. By device type the market is further segmented into inhalation devices, injection devices, solid dosage forms and others. Whereas injection devices are further sub segmented into handheld devices and wearable devices. Based on technology the market is categorized into Bluetooth, smart phone apps, near field communication (NFC) and emergency technologies. By application the market is further segmented into diabetes, cardiovascular diseases, autoimmune diseases, hormones replacement, neurology, addiction, respiratory diseases and others. Based on end users the market is categorized into hospitals, clinics and homecare settings.

Connected Injectable drug delivery devices market

Connected injectable drug delivery devices market is further analyzed on the basis of regions such as: North America, Europe, Asia-Pacific and Row.

Sample Companies profiled in this report are:
  • Phillips-Medisize Corporation (U.S.),
  • West Pharmaceutical Services, Inc. (U.S.),
  • Biocorp (France),
  • Aterica, Inc. (Canada),
  • Unilife Corporation (U.S.),
  • 10+.

Growing prevalence of chronic diseases like diabetes, cardiovascular disease, and cancer coupled with increasing compliance to the treatment owing to use of these devices. Increased interest of pharmaceutical or medical devices companies to surge consumer compatibility and application is expected to propel the growth of the market in the near future.

The research methodology opted for this report incorporates initial segregation of the market by device type, technology, application, end user and region. This was followed by mining of market volume and revenue of different device type of connected injectable drug delivery devices employed by various applications with respect to regions is considered. Bottom up approach was then followed for estimating the global market size and its forecast for period 2017 to 2023. The data figures and supporting insights so collated were validated through primary research process by Key Opinion Leaders (KOLs) which comprised of manufacturers, distributors, suppliers, associations and end users.
1. Connected Injectable Drug Delivery Devices Market - Overview
2. Connected Injectable Drug Delivery Devices Market - Executive Summary 
3. Connected Injectable Drug Delivery Devices - Market Landscape
   3.1. Market Share Analysis
   3.2. Comparative Analysis
      3.2.1. Product Benchmarking
      3.2.2. End User Profiling
      3.2.3. Top 5 Financials Analysis
      3.2.4. Patent Analysis
4. Connected Injectable Drug Delivery Devices Market - Forces
   4.1. Drivers
   4.2. Constraints & Challenges
   4.3. Porter’s Five Forces Analysis
      4.3.1. Bargaining Power of Suppliers
      4.3.2. Bargaining Power of Buyers
      4.3.3. Threat of New Entrants
      4.3.4. Threat of Substitutes
      4.3.5. Degree of Competition
5. Connected Injectable Drug Delivery Devices Market - Strategic Analysis
   5.1. Value Chain Analysis
   5.2. Pricing Analysis
   5.3. Opportunities Analysis
   5.4. Product/Market Life cycle Analysis
6. Connected Injectable Drug Delivery Devices Market - By Device Type
   6.1. Introduction
   6.2. Inhalation devices
   6.3. Injection Devices
      6.3.1. Handheld Devices
      6.3.2. Wearable Devices
   6.4. Solid Dosage Forms
   6.5. Others
7. Connected Injectable Drug Delivery Devices Market - By Technology
   7.1. Introduction
   7.2. Bluetooth
   7.3. Smart Phone Apps
   7.4. Near Field Communication
   7.5. Emergency Technologies
8. Connected Injectable Drug Delivery Devices Market - By Application
   8.1. Introduction
   8.2. Diabetes
   8.3. Cardiovascular Diseases
   8.4. Autoimmune Diseases
   8.5. Hormones Replacement
   8.6. Neurology
   8.7. Addiction
   8.8. Respiratory Diseases
   8.9. Others
9. Connected Injectable Drug Delivery Devices Market - By End User
   9.1. Introduction
   9.2. Hospitals
   9.3. Clinics
   9.4. Homecare Settings
10. Connected Injectable Drug Delivery Devices Market - By Geography
   10.1. Introduction
   10.2. North America
      10.2.1. U.S.
      10.2.2. Canada
      10.2.3. Mexico
   10.3. Europe
      10.3.1. U.K.
      10.3.2. Germany 
      10.3.3. France
      10.3.4. Italy
      10.3.5. Rest of Europe
   10.4. Asia-Pacific
      10.4.1. China
      10.4.2. Japan
      10.4.3. India
      10.4.4. Australia & New Zealand
      10.4.5. Rest of Asia-Pacific
   10.5. Row
      10.5.1. South America
      10.5.2. Middle East
      10.5.3. Africa
11. Connected Injectable Drug Delivery Devices - Market Entropy
   11.1. Expansion
   11.2. Technological Developments
   11.3. Merger & Acquisitions, and Joint Ventures
   11.4. Supply- Contract
12. Company Profiles (Overview, Financials, SWOT Analysis, Developments, Product Portfolio)
   12.1. Phillips-Medisize Corporation
   12.2. West Pharmaceutical Services, Inc.
   12.3. Biocorp
   12.4. Aterica, Inc.
   12.5. Unilife Corporation
   12.6. Panasonic Corporation
   12.7. Propeller Health
   12.8. Qualcomm Technologies, Inc.
   12.9. Haselmeier
   12.10. SHL Group
*More than 10 Companies are profiled in this Research Report*
"*Financials would be provided on a best efforts basis for private companies"
13. Appendix
   13.1. Abbreviations
   13.2. Sources
   13.3. Research Methodology
   13.4. Bibliography
   13.5. Compilation of Expert Insights
   13.6. Disclaimer
Please select Licence
Single User Licence:
US $4250
Corporate User Licence:
US $6250
Related Reports
0px;">Scroll